Brief: Ideaya Biosciences To Announce Topline Results From Phase 2/3 Optimum-02 Trial In Metastatic Uveal Melanoma On Monday, April 13, 2026
10/04/2026 21:19
April 10 (Reuters) - IDEAYA Biosciences Inc IDYA.O: IDEAYA BIOSCIENCES TO ANNOUNCE TOPLINE RESULTS FROM PHASE 2/3 OPTIMUM-02 TRIAL IN METASTATIC UVEAL MELANOMA ON MONDAY, APRIL 13, 2026 Source text: ID:nPn9lJtpra Further company coverage: IDYA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on IDEAYA Biosciences
See all newsBrief: Ideaya Biosciences And Servier Announce Data From Three Clinical Trials At Esmo 2026 Supporting The Potential Of Darovasertib To Become A Foundational New Therapy For Patients Across The Treatment Journey Of Uveal Melanoma
Brief: Ideaya Biosciences Announces The Promotion Of Dr. Michael White To President, Research And Development
Brief: Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Ideaya Biosciences Inc Reports Results For The Quarter Ended June 30: Earnings Summary
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj